165-P: Observations on class II HLA and genetic susceptibilty of primary antiphosphlipid (hughes) syndrome in Arab patients

Attia, Haider M. Al; Santhosh, Anitha; Farhan, Maha M. Al

doi:10.1016/j.humimm.2007.08.188

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the beginning of this century, in a cohort of 53 Caucasian APS patients in the UK, Caliz et al [90] established that the haplotypes DQB1*0301/4-DQA1*0301/2-DRB1*04 and DQB1*0604/5/6/7/9-DQA1*0102-DRB1*1302 were more frequent in patients with primary APS than in controls. The similar conclusions on the role of the MHC come from studies from Mexico [91], the UK [92], and the United Arab Emirates [93]. All studies showed a close link between APS and expression of several HLA genes.…”

Section: Aps: Genetic Predisposition and Family Studiessupporting

confidence: 64%

MicroRNA (miRNA): A New Dimension in the Pathogenesis of Antiphospholipid Syndrome (APS)

Kotyla

Islam

2020

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are single-stranded, endogenous RNA molecules that play a significant role in the regulation of gene expression as well as cell development, differentiation, and function. Recent data suggest that these small molecules are responsible for the regulation of immune responses. Therefore, they may act as potent modulators of the immune system and play an important role in the development of several autoimmune diseases. Antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by venous and/or arterial thromboses and/or recurrent fetal losses in the presence of antiphospholipid antibodies (aPLs). Several lines of evidence suggest that like other autoimmune disorders, miRNAs are deeply involved in the pathogenesis of APS, interacting with the function of innate and adaptive immune responses. In this review, we characterize miRNAs in the light of having a functional role in the immune system and autoimmune responses focusing on APS. In addition, we also discuss miRNAs as potential biomarkers and target molecules in treating APS.

show abstract

Section: Aps: Genetic Predisposition and Family Studiessupporting

confidence: 64%

MicroRNA (miRNA): A New Dimension in the Pathogenesis of Antiphospholipid Syndrome (APS)

Kotyla

Islam

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In fact, the same associations have been found among aPLs and the HLA system in primary APS and in APS secondary to SLE (35, 51, 52). In addition, the pattern of HLA associations is also influenced by the different ethnic groups (36, 53, 54).…”

Section: Genetic Risk Factors Of Athero-thrombosis In Apsmentioning

confidence: 99%

New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches

et al. 2019

View full text Add to dashboard Cite

Antiphospholipid Syndrome (APS) is an autoimmune disorder, characterized by pregnancy morbidity and/or a hyper coagulable state involving the venous or the arterial vasculature and associated with antiphospholipid antibodies (aPL), including anti-cardiolipin antibodies (aCL), anti-beta2-glycoprotein I (anti-ß2GPI), and Lupus anticoagulant (LA). In recent years there have been many advances in the understanding of the molecular basis of vascular involvement in APS. APS is of multifactorial origin and develops in genetically predisposed individuals. The susceptibility is determined by major histocompatibility complex (MHC). Different HLA-DR and HLA-DQ alleles have been reported in association with APS. Moreover, MHC II alleles may determine the autoantibody profile and, as such, the clinical phenotype of this disease. Besides, polymorphisms in genes related to the vascular system are considered relevant factors predisposing to clinical manifestations. Antiphospholipid antibodies (aPL) induce genomic and epigenetic alterations that support a pro- thrombotic state. Thus, a specific gene profile has been identified in monocytes from APS patients -related to aPL titres in vivo and promoted in vitro by aPL- explaining their cardiovascular involvement. Regarding epigenetic approaches, we previously recognized two miRNAs (miR-19b/miR-20a) as potential modulators of tissue factor, the main receptor involved in thrombosis development in APS. aPLs can further promote changes in the expression of miRNA biogenesis proteins in leukocytes of APS patients, which are translated into an altered miRNA profile and, consequently, in the altered expression of their protein targets related to thrombosis and atherosclerosis. MicroRNAs are further released into the circulation, acting as intercellular communicators. Accordingly, a specific signature of circulating miRNAs has been recently identified in APS patients as potential biomarkers of clinical features. Genomics and epigenetic biomarkers might also serve as indices for disease progression, clinical pharmacology, or safety, so that they might be used to individually predict disease outcome and guide therapeutic decisions. In that way, in the setting of a clinical trial, novel and specific microRNA–mRNA regulatory networks in APS, modified by effect of Ubiquinol treatment, have been identified. In this review, current and previous studies analyzing genomic/epigenetic changes related to the clinical profile of APS patients, and their modulation by effect of specific therapies, are discussed.

show abstract

165-P: Observations on class II HLA and genetic susceptibilty of primary antiphosphlipid (hughes) syndrome in Arab patients

Cited by 2 publications

References 0 publications

MicroRNA (miRNA): A New Dimension in the Pathogenesis of Antiphospholipid Syndrome (APS)

MicroRNA (miRNA): A New Dimension in the Pathogenesis of Antiphospholipid Syndrome (APS)

New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches

Contact Info

Product

Resources

About